Clinical Trials Logo

Cognitive Dysfunction clinical trials

View clinical trials related to Cognitive Dysfunction.

Filter by:

NCT ID: NCT04212442 Completed - Physical Activity Clinical Trials

Improving Aging in Place in Subsidized Housing

Start date: January 13, 2020
Phase: N/A
Study type: Interventional

This pilot study will evaluate the feasibility and preliminary effectiveness of an adapted version of the Function Focused Care intervention, delivered by telephone, for improving aging in place for older adults living in subsidized housing. The study will include participants with and without mild cognitive impairment or mild dementia and will examine whether the study outcomes differ by cognitive status. Findings from this study will provide new information about how to optimize function and physical activity among older adults with and without cognitive impairment living in subsidized housing.

NCT ID: NCT04210778 Completed - Cancer Clinical Trials

Combined Model of Online Remote Interventions for Cancer-Related Cognitive Impairment

CRCI
Start date: February 26, 2018
Phase: N/A
Study type: Interventional

Cancer survival rates have increased dramatically in recent years. However, many survivors report cognitive decline following treatment, which significantly impairs their quality of life. Online cognitive training programs have shown promise in improving cognitive functions in cancer survivors, but most studies report limited impact of training on everyday function. A complementary treatment approach is functional treatment delivered by occupational therapists, which directly targets daily function. Combining the two approaches has the potential to overcome the limitations of both approaches, enabling improved cognitive functions and transfer to daily function. Remotely-administrated interventions further make treatment accessible and cost-effective. The current study is aimed at testing the efficacy of a novel, combined, remotely-delivered treatment approach: Cognitive Retraining and Functional Treatment(CRAFT), using a Randomized Controlled Trial (RCT) design. 90 cancer survivors will be randomly assigned to receive 15 weeks of either the combined treatment, computerized training only, or treatment-as-usual. Outcomes will be assessed at completion, and following 3 months of no contact, to test immediate and enduring effects of treatment. Baseline predictors for treatment response will be further assessed. Positive results in the proposed study could potentially change the therapeutic landscape for rehabilitation of cancer-related cognitive decline, which currently impair the lives of millions worldwide.

NCT ID: NCT04210713 Completed - Inflammation Clinical Trials

Neuroimmune Dysfunction in Alcohol Use Disorder

Start date: February 3, 2020
Phase: Phase 1
Study type: Interventional

The objective of this proposal is to advance medication development for alcohol use disorder by examining the efficacy and mechanisms of action of minocycline, a neuroimmune modulator, as a potential treatment. This study has important clinical implications, as the available treatments for alcohol use disorder are only modestly effective and testing novel medications is a high research priority.

NCT ID: NCT04206670 Completed - Alzheimer Disease Clinical Trials

In-Home Technology for Caregivers of People With Dementia and Mild Cognitive Impairment

Start date: March 10, 2020
Phase: N/A
Study type: Interventional

This study aims to develop and evaluate new in-home supportive technology that is designed to alleviate anxiety, burden, and loneliness in spousal and familial caregivers of individuals with Alzheimer's disease, other dementias, or mild cognitive impairment.

NCT ID: NCT04200911 Completed - Alzheimer Disease Clinical Trials

Cognition, Age, and RaPamycin Effectiveness - DownregulatIon of thE mTor Pathway

CARPE_DIEM
Start date: June 1, 2020
Phase: Early Phase 1
Study type: Interventional

Evaluation of central nervous system penetration of orally administered Rapamune (RAPA) in older adults with Mild Cognitive Impairment (MCI) or early Alzheimer's disease (AD) and investigate associated safety, tolerability, target engagement, cognition, and functional status as initial proof-of-concept study

NCT ID: NCT04198038 Completed - Clinical trials for Cognitive Impairment

Family-Centered Songwriting in Pediatric Palliative Care

Start date: March 11, 2020
Phase: N/A
Study type: Interventional

This study evaluates the feasibility and efficacy of a family-centered songwriting intervention for cognitively-impaired children referred to a palliative care service.

NCT ID: NCT04195230 Completed - Clinical trials for Age-related Cognitive Decline

Cognitive Multi-Tasking Training in Healthy Older Adults

Start date: January 2, 2020
Phase: N/A
Study type: Interventional

This study evaluated the feasibility of a remote web-based ecological cognitive training protocol to healthy older adults. The training protocol involves 5 training sessions.

NCT ID: NCT04191642 Completed - Clinical trials for Postoperative Complications

Correlation of NLRP3 With Cognitive Dysfunction Early After Heart Valve Replacement Surgery

Start date: April 1, 2019
Phase:
Study type: Observational

The investigators decided to assess the prognostic value of NLRP3 inflammasome level in early after heart valve replacement surgery and whether it was related to postoperative cognitive dysfunction. Study population included 90 subjects. Neuropsychological tests were administrated one day before surgery and seven days after surgery. Before induction of anesthesia, before the end of the operation, 7 days after the operation, peripheral venous blood was sampled to measure IL-1B, IL-18 and NLRP3 inflammatory protein expression in peripheral blood monocytes. Analyze the data and draw conclusions.

NCT ID: NCT04191486 Completed - Clinical trials for Mild Cognitive Impairment

Efficacy and Safety of T-817MA in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD

Start date: December 24, 2019
Phase: Phase 2
Study type: Interventional

Primary objective is to evaluate the neuroprotective effect of T-817MA on Tau protein phosphorylated at threonine 181 (p-tau 181) in cerebrospinal fluid (CSF) compared with placebo in patients with a diagnosis of MCI due to AD or mild AD. Secondary objectives are: 1. To evaluate in patients on T-817MA and placebo: - cognitive function measured by the Clinical Dementia Rating Scale Sum of Boxes (CDR-sb) and working memory and attention domain as measured by the Cognitive Functional Composite (CFC). - AD-related biomarkers in CSF and plasma - imaging analysis using volumetric magnetic resonance imaging (vMRI) - alpha/theta ratio of the electroencephalogram (EEG) 2. To evaluate the safety of T-817MA by clinical laboratory tests and adverse events (AEs). 3. To evaluate the pharmacokinetics of T-817MA

NCT ID: NCT04185298 Completed - Clinical trials for Amnestic Mild Cognitive Impairment

mSIM: Mobile Simultaneous Aerobic Exercise and Memory Training Intervention for Amnestic Mild Cognitive Impairment

mSIM
Start date: October 1, 2019
Phase: N/A
Study type: Interventional

The mSIM study involves developing and conducting feasibility testing of a web-based application that will deliver mobile-based simultaneous exercise and memory skills training program (mSIM) for amnesic Mild Cognitive Impairment (aMCI) patients. The randomized control trial (RCT) will evaluate the efficacy of mSIM on memory performance and everyday functioning using 2 study arms (Group 1 activity monitoring control (via Fitbit) (CON) vs Group 2 mSIM intervention plus activity monitoring via Fitbit). mSIM treatment response will be evaluated using neuropsychological and functional evaluation. Concentration levels of peripheral biomarkers Brain-derived neurotrophic factor (BDNF) and norepinephrine (NE) also be assessed.